Trial Profile
Prospective, Randomised, Double Blind, Placebo Controlled Study of Treatment With Sublingual Immunotherapy of Depigmented and Polymerised Allergen Extract of O. Europaea in Two Groups of Patients With Allergic Rhinitis /Rhinoconjunctivitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tree pollen allergy immunotherapy (Primary)
- Indications Rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Therapeutic Use
- Acronyms GPIT
- Sponsors Leti
- 05 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2009 Planned end date changed from 1 Sep 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
- 10 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.